Patients who pay privately for eye surgery believe they are purchasing more just than an operation; they believe they are buying expertise, continuity, reassurance, and accountability.

They hold the opinion – whether rightly or wrongly – that if a recognized complication occurs, the same system that delivered their surgery will also remain responsible for managing it. In the patient’s mind, they are purchasing not merely a surgical procedure – they are purchasing an outcome.

However, in modern private ophthalmology that assumption is not always correct.

While this article is primarily focused on the United Kingdom, where private ophthalmology operates alongside one of the world's most comprehensive publicly funded healthcare systems, it is also concerned with a broader international challenge. Even though the healthcare systems of countries can differ significantly, the accountability gap they create can look surprisingly similar. And this accountability gap is all too clear when surgical complications arise – complications expose the difference between performing a procedure and owning an outcome.

I believe this difference deserves greater scrutiny than it currently receives.

The £10,000 question

Take, for example, this scenario: A patient pays £10,000 for bilateral lens replacement surgery in the UK. They have chosen a recognized consultant ophthalmic surgeon operating within a respected private healthcare brand. They have undergone extensive diagnostics, selected a premium intraocular lens, and committed significant personal funds to achieving spectacle independence. They expect premium care. But then, during surgery on the first eye, a dropped nucleus occurs.

The complication itself is recognized, consented for in principle and clinically manageable. The patient is reassured that a vitreoretinal surgeon will be required to retrieve the retained lens material. But then the conversation changes. The vitreoretinal surgeon, it turns out, is external. The hospital does not provide an integrated retinal service; the private pathway effectively stops.

The patient is then advised to attend an NHS eye casualty department and await treatment through a local vitreoretinal service. They spend days with reduced vision, enter a healthcare system they believed they had temporarily left behind, and ultimately undergo surgery with a specialist they have never met.

This scenario is, of course, uniquely British. And while the quality of NHS vitreoretinal care may be exceptional, that is not the issue. The issue here is continuity and ownership. The cataract surgery was paid for and private, but then the complication management was not.

In the US, this type of scenario would usually unfold differently because there is no NHS to absorb that patient's care. Instead, patients are commonly referred to an independent retina specialist, another ophthalmology group, or even a separate hospital system. This transfer may require fresh insurance authorization, create additional out-of-pocket costs, and expose the patient to separate billing arrangements.

The structural differences between the UK and US healthcare systems are profound. However, the patient experience can often be remarkably similar. The pathway originally purchased by the patient has ended and responsibility has shifted elsewhere.

This is not a story about negligence. A dropped nucleus is a recognized complication of cataract and refractive lens exchange surgery, occurring even in the most skilled hands (1). [1] The clinical issue is not what happened in theatre itself, but what happened afterwards. And what happened afterwards reveals a structural problem in private ophthalmology that the profession has, to date, been reluctant to name.

Three things that patients confuse

When a patient pays for private surgery, they generally believe they are paying a single organization for a single outcome. But in reality, almost every private ophthalmic procedure in the UK is delivered by three distinct entities, each with its own responsibilities, liabilities and commercial incentives:

     1. The surgeon.
     2. The hospital.
     3. The provider or brand.

To the patient, these entities frequently appear as one integrated organization. In practice, they are not.

The surgeon performs the operation, makes the clinical decisions, and carries personal professional liability through a medical defense organization. They own the clinical relationship.

The hospital provides theatres, nursing staff, sterilization services, equipment processing, medication supply chains, and governance structures. They own the environment in which care is delivered.

The provider or brand markets the service, controls the patient journey, manages communication, and often determines pricing. It owns the patient experience.

So while patients frequently assume these entities are one, they may instead be three separate organizations with three separate contracts, three separate insurance arrangements, and three separate limits of responsibility.

This is not at all unusual. It is the operating model of much of British private healthcare – most consultants will remain self-employed, most private hospitals will contract practitioners rather than employ them, and many patient-facing healthcare brands do not own the facilities in which surgery is performed.

The fragmentation itself is not a scandal. It becomes problematic only at one specific moment: the moment something goes wrong.

Despite having a fundamentally different healthcare structure in place, I believe readers in the US will recognize a similar challenge. In the US, care may be distributed across physician groups, ambulatory surgery centers, hospitals, specialist practices, and insurance networks. The organizational architecture differs significantly, but the accountability question remains remarkably similar. Patients believe they have purchased one accountable outcome, but the care itself may be delivered by multiple organizations all with different responsibilities.

Consent is not a contract

Before surgery, patients will sign a consent form, but they do not necessarily sign a contract. The consent form records that they understand the risks of surgery and authorize the surgeon to proceed, but it will not typically explain what happens if those stated risks ever materialize.

In most private ophthalmic pathways in the UK, there is no document routinely provided before surgery that answers the questions that matter most after a complication: Who manages a dropped nucleus? Where will this treatment take place? Is vitreoretinal cover available within the same organization? Who funds tertiary opinions? Are additional diagnostics included? Are complication-related medications covered? At what point does the surgical package end?

I would invite any reader of this journal to test the proposition – visit the website of any private ophthalmology provider in the UK and attempt to determine, before booking a consultation, precisely what happens if a serious complication occurs and which organization assumes responsibility for managing it.

In most cases, the answer is very difficult to find. This distinction is particularly important in Britain, because patients often assume that paying privately guarantees continuity of care. The consent form will explain risk, but it will rarely explain ownership.

The legal framework differs internationally. In the UK, the Montgomery standard requires disclosure of risks that a reasonable patient would regard as material. In the US, informed consent standards vary by state and may be based upon either a reasonable-physician or reasonable-patient threshold.

And yet while these two legal mechanisms differ, neither system routinely requires providers to explain who owns the complication once it occurs. That is the accountability gap this article seeks to examine: you sign a consent form; you do not sign a contract. For the patient, the difference remains invisible until it matters.

Complications reveal the system

A surgical system that performs well on uncomplicated days reveals very little about itself. Any competent pathway can deliver an excellent outcome following routine cataract surgery. What separates a robust system from a fragile one is what happens after a complication occurs. Complications act as stress tests for the system – they reveal whether accountability has been designed into the pathway from the outset or whether responsibility becomes fragmented between multiple organizations.

Example 1: The dropped nucleus

Posterior capsule rupture historically occurred in around 1.9 percent of cataract operations in large UK datasets, although the rate has fallen significantly and now stands at 0.69 percent in the most recent RCOphth National Ophthalmology Database audit (2, 3). The rarer subset involving posteriorly dislocated nuclear fragments occurs in approximately 0.07 to 0.17 percent of cases (4, 5).

The complication is recognized, accepted, and manageable. The clinical pathway is well established, but the accountability pathway often is not. So who coordinates vitreoretinal intervention? Who funds it? Within what timeframe? In which hospital? And under which surgeon?

If the answer involves transfer into a different healthcare system, a different organization, or a different provider network, then accountability has already become fragmented.

The concern here is not the quality of care that follows. The concern is about the continuity of responsibility. A complication pathway should be part of the surgery itself, and if a provider cannot explain how complications are managed, then it has not finished designing the operation.

Example 2: PRK and corneal haze

Corneal haze following photorefractive keratectomy remains uncommon but not rare (7). Its management is straightforward in principle and prolonged in practice: repeated imaging; extended steroid therapy; multiple reviews; further intervention (if required).

The financial burden for this complication can become significant, and so can the psychological burden to the patient.

The central question here becomes simple: was the patient purchasing a procedure or were they purchasing an outcome-supported journey?

Many current private ophthalmic contracts continue to define the former while marketing language often implies the latter.

Example 3: Endophthalmitis

Endophthalmitis following cataract surgery is rare, occurring in approximately 0.02 to 0.05 percent of cases following modern prophylactic protocols (8, 9).

Its clinical management is clear; its accountability pathway is not. Root-cause analysis may involve surgical technique, theatre protocols, sterilization processes, consumable supply chains, pharmacy systems, and post-operative care pathways. Each of these systems may be owned by a different organization, and they may each carry separate liability and retain separate legal representation.

However, to the patient these distinctions are invisible. They only know one thing: they trusted the system. Yet what appears to be a system may, under scrutiny, prove to be simply a collection of contracts.

Insurance is not ownership

Every reputable surgeon carries indemnity, every reputable hospital carries corporate cover, and every responsible healthcare organization has governance systems designed to manage risk. These protections are essential, but they are still not ownership.

Insurance mechanisms differ significantly between countries. In the UK, responsibility is divided between consultant indemnity providers, hospital liability arrangements, and organizational governance structures. Whereas in the US, responsibility is more likely to involve commercial malpractice insurers, hospital liability carriers, and insurer-provider contractual arrangements.

These differences influence how claims are funded and managed, but they do not solve the underlying problem. Insurance allocates financial responsibility after harm has occurred, but it does not coordinate care, provide continuity of care, or own the final outcome.

Ownership of the outcome is something more demanding. It requires a provider to remain accountable for the patient journey regardless of which organization, individual, or system component contributed to the complication.

That principle is now being explored by a small number of vertically integrated ophthalmic practices. Such models remain the exception rather than the rule, and yet they point toward a future in which accountability extends beyond the procedure itself.

Industry questions

If private ophthalmology is to mature beyond a competition based solely on technology, branding, and marketing, then several questions deserve to be openly discussed and scrutinized: Should providers be required to disclose, in writing, their complication pathway? Should patients be told explicitly whether vitreoretinal cover is integrated, contracted, or absent? Should enhancement and complication exclusions be subject to clearer standards? Should premium surgical packages routinely include complication-related medications, imaging, and tertiary consultations? And what constitutes a genuinely integrated private surgical pathway in 2026?

These are not questions for one sole provider; they are questions for the entire profession.

The next era of transparency

Ophthalmology has spent the past decade becoming increasingly comfortable with transparency in areas where transparency is comparatively straightforward (e.g. outcomes data, lens technology, laser platforms, refractive predictability, registry performance, patient reviews). The National Ophthalmology Database has positioned UK ophthalmology as a global leader in surgical outcome transparency, and the US has developed an impressive data infrastructure through the IRIS Registry, albeit within a more fragmented healthcare environment.

Both of these systems have become increasingly transparent about outcomes, and yet neither has become fully transparent about accountability.

In light of this, I believe the next era of transparency will not be technological but structural. It will require providers to explain, before surgery takes place, what happens when surgery does not go according to plan. It will require full transparency as to who will coordinate the complication, who will fund the treatment, who will arrange the referral, who will remain accountable six months later, and, most importantly, who owns the final outcome.

The accountability gap is not exclusively a UK problem and nor is it exclusively an American one. Different healthcare systems simply expose this gap in different ways. In Britain, the gap often becomes visible when responsibility passes from the private sector into the NHS. In the US, it becomes visible through fragmented referrals, insurance approvals, provider networks, and separate billing arrangements.

And so while these mechanisms differ, the patient's essential question remains the same: when something goes wrong, who is responsible for making it right?

Until that question can be answered clearly – explicitly and in writing – by every provider and in every healthcare system, the accountability gap remains. And unfortunately, patients will continue to fall through that gap until it is finally addressed.